These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25490450)

  • 1. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
    Srivastava K; Hu J; Korn C; Savant S; Teichert M; Kapel SS; Jugold M; Besemfelder E; Thomas M; Pasparakis M; Augustin HG
    Cancer Cell; 2014 Dec; 26(6):880-895. PubMed ID: 25490450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel.
    Akiyama K; Maishi N; Ohga N; Hida Y; Ohba Y; Alam MT; Kawamoto T; Ohmura H; Yamada K; Torii C; Shindoh M; Hida K
    Am J Pathol; 2015 Feb; 185(2):572-80. PubMed ID: 25498238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
    Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
    Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer.
    Jellvert Å; Åhs D; Olausson J; Franck Lissbrant I; Damber JE; Welén K
    Acta Oncol; 2018 Jul; 57(7):895-901. PubMed ID: 29299975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
    Shi S; Tao L; Song H; Chen L; Huang G
    APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
    Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
    Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice.
    Jiang H; Tao W; Zhang M; Pan S; Kanwar JR; Sun X
    Cancer Invest; 2010 Jan; 28(1):74-84. PubMed ID: 20001297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic chemotherapy for advanced breast cancer patients.
    Cazzaniga ME; Dionisio MR; Riva F
    Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.
    Mazzieri R; Pucci F; Moi D; Zonari E; Ranghetti A; Berti A; Politi LS; Gentner B; Brown JL; Naldini L; De Palma M
    Cancer Cell; 2011 Apr; 19(4):512-26. PubMed ID: 21481792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2
    Harney AS; Karagiannis GS; Pignatelli J; Smith BD; Kadioglu E; Wise SC; Hood MM; Kaufman MD; Leary CB; Lu WP; Al-Ani G; Chen X; Entenberg D; Oktay MH; Wang Y; Chun L; De Palma M; Jones JG; Flynn DL; Condeelis JS
    Mol Cancer Ther; 2017 Nov; 16(11):2486-2501. PubMed ID: 28838996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
    Español AJ; Salem A; Di Bari M; Cristofaro I; Sanchez Y; Tata AM; Sales ME
    PLoS One; 2020; 15(9):e0226450. PubMed ID: 32911509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
    Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.
    Huang H; Lai JY; Do J; Liu D; Li L; Del Rosario J; Doppalapudi VR; Pirie-Shepherd S; Levin N; Bradshaw C; Woodnutt G; Lappe R; Bhat A
    Clin Cancer Res; 2011 Mar; 17(5):1001-11. PubMed ID: 21233403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
    Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
    Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.
    Naganuma Y; Choijamts B; Shirota K; Nakajima K; Ogata S; Miyamoto S; Kawarabayashi T; Emoto M
    Cancer Sci; 2011 Aug; 102(8):1545-52. PubMed ID: 21631643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.